Hexarelin peptide is a synthetic growth hormone-releasing peptide (GHRP) that belongs to the class of hexapeptides. It is composed of six amino acids and is speculated by researchers to host the potential to stimulate the release of growth hormone.
Hexarelin, or Examorelin, is a manufactured derivative of ghrelin, displaying a notable resemblance to GHRP-6. The sole disparity between Hexarelin and GHRP-6 lies in incorporating two methyl groups within the molecular composition of GHRP-6. Studies suggest that, like other ghrelin analogs, this peptide may retain its activity when presented and exhibit a high level of selectivity in its mechanism of action. The phenomenon has been thoroughly investigated in cardiac cell viability following ischemia and nutrient deprivation.
Hexarelin Peptide Research
Hexarelin Peptide and Muscle
Research studies have speculated that the peptide may exhibit cytoprotective effects on muscle cells and may possibly not possess exclusive utility for cardiac tissue. Research investigations on Hexarelin and GHRP-6 peptides have been conducted to examine their potential role in regulating calcium flux and mitigating mitochondrial dysfunction in the skeletal muscles of rats afflicted with cachexia, a condition characterized by severe weight loss as brought on by radiation.
The researchers’ findings suggest that the secretagogue might safeguard skeletal muscle against mitochondrial impairment and enhance the healing of lean mass. Additionally, it seems to preserve the viability of muscle cells by upholding the integrity of mitochondria. Mitochondria, by their energy provisioning, facilitate the execution of routine physiological processes by muscle cells. The disturbance of calcium ion regulation is a commonly observed phenomenon during cachexia, and it serves as a significant contributing factor to the changes in muscle mass and lean body mass that occur from radiation. Nevertheless, investigations purport that presenting Hexarelin and GHRP-6 might possibly restore adequate calcium regulation within similar circumstances.
Hexarelin Peptide and the Heart
Hexarelin has been suggested to influence the cardiovascular system by interacting with the CD36 receptor and the growth hormone secretagogue receptor (GHSR). Studies on murine models have suggested that the peptide may protect cardiac cells in cardiac arrest. The researchers also speculate that Hexarelin “has the potential to serve as a promising agent for certain cardiovascular conditions.”
Scientists propose that the peptide may interact with the receptors above, thereby inhibiting apoptosis of the cardiac cells. Licensed professionals hypothesize that the peptide could potentially enhance cardiac function by promoting cardiac cell survival and decreasing malondialdehyde levels, a biomarker associated with cardiac cell death.
Remarkably, the investigation additionally proposed that GHRP-6 may exhibit a partial functionality property compared to ghrelin. Hexarelin has also been suggested to mitigate oxidative stress in cardiac cells during cardiac failure and inhibit myocardial remodeling in rats. Cardiac remodeling is a physiological process that results in a reduction in cardiac function and has the potential to lead to mortality.
Nevertheless, studies suggest that the rats presented with GHRP-6 or Hexarelin appeared to exhibit notable cardiac function enhancements compared to the control group. The functional aspects of the peptide are governed by molecular mechanisms that involve upregulation of phosphatase and tension homolog (PTEN) activity, leading to a subsequent decrease in protein kinase B levels.
PTEN is responsible for regulating cellular regeneration, whereas protein kinase B is considered to play a crucial role in the modulation of cell survival. Research suggests that GHRP-6 and Hexarelin may possibly modulate cardiac remodeling by inducing a shift in the autonomic nervous system response from sympathetic (which encompasses heightened blood pressure, heart rate, etc.) to parasympathetic. This regulatory measure may enhance short-term outcomes. Furthermore, in experimental research involving rat models, a noteworthy reduction in cardiac tissue scarring was speculated when the peptide was introduced following cardiac arrest.
Hexarelin Peptide and Metabolism
Dyslipidemia refers to the state of having increased levels of lipids in the bloodstream. Notably, it also serves as an autonomous contributing element to the initiation of diabetes, even in instances of low body fat. A comprehensive grasp of the condition elucidates the correlation between physiology and dietary patterns. Studies on GHRP-6 and Hexarelin have suggested the peptides’ potential to mitigate or rectify dyslipidemia in the context of insulin resistance, which serves as the initial stage in the progression toward diabetes. Research suggests that the peptide might potentially mitigate hyperglycemia and enhance insulin sensitivity in rodent models.
Recent Advances in Hexarelin Peptide Research
Findings imply that certain peptides, apparently exemplified in this case with Hexarelin, have facilitated scientific investigations into the intricacies of cardiac ailments, ultimately culminating in cardiac insufficiency and mortality. Research investigations involving the peptide have suggested several novel pathways for comprehending cardiac function in physiological well-being and pathological conditions.
Check this article for more Hexarelin info.
References
[i] Ghigo E, Arvat E, Gianotti L, Grottoli S, Rizzi G, Ceda GP, Boghen MF, Deghenghi R, Camanni F. Short-term administration of intranasal or oral Hexarelin, a synthetic hexapeptide, does not desensitize the growth hormone responsiveness in human aging. Eur J Endocrinol. 1996 Oct;135(4):407-12. doi: 10.1530/eje.0.1350407. PMID: 8921821.
[ii] Bresciani E, Rizzi L, Coco S, Molteni L, Meanti R, Locatelli V, Torsello A. Growth Hormone Secretagogues and the Regulation of Calcium Signaling in Muscle. Int J Mol Sci. 2019 Sep 5;20(18):4361. doi: 10.3390/ijms20184361. PMID: 31491959; PMCID: PMC6769538.
[iii] Mao Y, Tokudome T, Kishimoto I. The cardiovascular action of hexarelin. J Geriatr Cardiol. 2014 Sep;11(3):253-8. doi: 10.11909/j.issn.1671-5411.2014.03.007. PMID: 25278975; PMCID: PMC4178518.
[iv] Mosa R, Huang L, Wu Y, Fung C, Mallawakankanamalage O, LeRoith D, Chen C. Hexarelin, a Growth Hormone Secretagogue, Improves Lipid Metabolic Aberrations in Nonobese Insulin-Resistant Male MKR Mice. Endocrinology. 2017 Oct 1;158(10):3174-3187. doi: 10.1210/en.2017-00168. PMID: 28977588; PMCID: PMC5659698.
[v] Imbimbo BP, Mant T, Edwards M, Amin D, Dalton N, Boutignon F, Lenaerts V, Wüthrich P, Deghenghi R. Growth hormone-releasing activity of hexarelin in humans. A dose-response study. Eur J Clin Pharmacol. 1994;46(5):421-5. doi: 10.1007/BF00191904. PMID: 7957536.